Mirum Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (MIRM) on May 18, 2026, covering events occurring on May 12, 2026, and May 15, 2026. The filing details the entry into a material definitive agreement involving the issuance of convertible senior notes and a concurrent note exchange transaction.
Key Financial Metrics and Capital Structure
- Debt Issuance: Issued $690.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032.
- Net Proceeds: Estimated at approximately $671.6 million after deducting discounts, commissions, and offering expenses.
- Interest Rate: 0.00% (no regular interest; principal does not accrete).
- Maturity Date: June 1, 2032.
- Conversion Terms: Initial conversion rate of 7.1971 shares per $1,000 principal amount (approx. $138.94 per share). Maximum potential issuance of 6,455,778 shares upon full conversion.
- Note Exchange Transaction: The Company expects to use approximately $475.0 million of net proceeds to pay the cash portion of consideration to exchange approximately $237.2 million of its existing 4.00% Convertible Senior Notes due 2029. This involves issuing 3,220,529 shares of common stock.
Material Changes and Use of Proceeds
The primary material change is the addition of $690.0 million in senior unsecured debt obligations. The Company intends to use the net proceeds for the following purposes:
- Payment of the cash portion of the Note Exchange Transactions ($475.0 million).
- General corporate purposes, including potential acquisitions of complementary products, technologies, intellectual property, or businesses.
Outlook, Risks, and Contingencies
Redemption and Repurchase Rights: The Notes are not redeemable by the Company before June 6, 2029. Upon a "Fundamental Change" (e.g., business combination or delisting), noteholders may require the Company to repurchase the Notes at par plus accrued interest.
Events of Default: Includes payment defaults, failure to comply with covenants regarding asset transfers, failure to convert notes, and bankruptcy events. Certain reporting covenant failures may result in special interest of up to 0.50% per annum rather than immediate acceleration.
Forward-Looking Statements: The filing includes forward-looking statements regarding the use of proceeds and future business strategy, subject to risks detailed in the Company's 2025 Form 10-K and Q1 2026 Form 10-Q.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $671.6 million.
- Confirm the exact number of shares issued in the Note Exchange Transaction and the impact on existing share count.
- Review the full Indenture (Exhibit 4.1) for specific definitions of "Fundamental Change" and "Make-Whole Fundamental Change" to understand dilution risks.
- Monitor the Company's stock price relative to the $138.94 conversion price to assess the likelihood of conversion or redemption triggers.
- Check subsequent filings for updates on the use of proceeds for acquisitions or general corporate purposes.